OPKO Health Inc.
Rating
Updated: Aug 11, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other inte...
Latest News
1 day ago · zacks.com
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
12 days ago · marketbeat.com
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 MonthsOPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
14 days ago · globenewswire.com
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare ConferenceMIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
27 days ago · zacks.com
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
29 days ago · zacks.com
Here's Why You Should Retain OPK Stock in Your Portfolio for NowOPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
1 month ago · zacks.com
OPK Raises $125 Million Against Royalties: What Investors Should KnowOPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
1 month ago · zacks.com
Is OPK Worth Buying as Valuation Meets Improving Business Trends?OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
1 month ago · zacks.com
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
1 month ago · zacks.com
OPKO Health Secures $125 Million Financing Against Mazdutide RoyaltiesOPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
1 month ago · globenewswire.com
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty InterestsTransaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside
Analyst Summary
Add to Watchlist
Select watchlists to add or remove OPK